Shionogi’s Oral Antiviral S-217622 Rapidly Clears COVID-19 Virus

Article

Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.

Today, Shionogi & Co., Ltd. announced positive trial data for their once-daily oral COVID-19 antiviral, S-217622. The studies examined the safety and efficacy of S-217622, an investigational 3CL protease inhibitor, in mainly vaccinated low-risk patients within 5 days of symptomatic COVID-19 infection.

This late-breaking data was presented April 23 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal. In stage 2/3 clinical trials, S-217622 was able to rapidly clear the COVID-19 virus.

In 2 different presentations, Shionogi shared the results from their phase 2/3 clinical trial of S-217622. The multicenter, randomized, placebo-controlled, double-blinded study included patients with asymptomatic, mild, or moderate COVID-19 infection. Participants were 12-70 years of age and had COVID-19 onset within 120 hours of study randomization.

Phase 1 and phase 2a included 69 patients, and phase 2b included 428 COVID-19 patients from Japan and South Korea. The primary purpose of the phase 2/3 clinical trial was to confirm S-217622’s antiviral effect and clinical symptom improvement when administered once a day for 5 days.

Compared to placebo, S-217622 significantly reduced viral RNA on days 2, 4, 6, and 9. On day 4 of the treatment (after receiving 3 doses), the proportion of patients with positive viral titer decreased by 90% compared to placebo. S-217622 also reduced infectious virus shedding by 1-2 days versus placebo.

Notably, there was no significant difference in the total score of 12 different COVID-19 symptoms between the S-217622 group and placebo group. However, the S-217622 group did report improvement in the composite score of 5 “respiratory and feverish” symptoms in post-hoc analysis.

The clinical trials showed S-217622 was well-tolerated; Shionogi reported few discontinuations due to drug, no serious adverse events, and no mortalities. Adverse events induced by S-217622 were mild-to-moderate and resolved without treatment.

Phase 3 of the phase 2/3 clinical trial is still ongoing. In the preliminary in vitro study, S-217622 exhibited similar antiviral activity against the Omicron BA.2 variant as it did against other, less infectious COVID-19 variants.

S-217622 was developed through the research efforts of Shionogi and Hokkaido University. SARS-CoV-2, the virus that causes COVID-19 infection, utilizes the 3CL enzyme for reproduction. By inhibiting the 3CL protease, S-217622 hinders the virus’s replication.

A separate global phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment (SCORPIO-HR), plans to recruit 1700 participants this year.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.